Related Experiment Videos
Diagnostic and prognostic markers for human prostate cancer
X Gao1, A T Porter, D J Grignon
1Department of Radiation Oncology, Wayne State University School of Medicine, Detroit, Michigan 48202, USA. xgao@shiffman.med.wayne.edu
The Prostate
|June 1, 1997
Summary
Prostate cancer diagnosis and treatment require better prognostic markers beyond prostate-specific antigen (PSA). Further research into novel diagnostic and prognostic markers is crucial for selecting optimal therapies.
Area of Science:
- Oncology
- Urology
- Biomarker Discovery
Background:
- Prostate cancer incidence and mortality are rising, particularly in aging populations.
- Early detection and accurate staging are critical for effective prostate cancer management.
- Current prognostic markers are insufficient for optimal therapeutic selection.
Purpose of the Study:
- To review potential diagnostic and prognostic markers for human prostate cancer.
- To evaluate established and investigational markers for their clinical utility.
- To identify needs for improved prostate cancer prognostication.
Main Methods:
- Comprehensive literature review of diagnostic and prognostic markers.
- Focus on recently identified novel markers.
- Discussion of markers with both diagnostic and prognostic value.
Main Results:
- Established prognostic indicators like histologic grade and DNA ploidy were not the focus.
- Novel diagnostic and prognostic markers have been identified.
- The review covers established, investigational, and prognostically relevant diagnostic markers.
Conclusions:
- Prostate-specific antigen (PSA) remains the primary marker for early diagnosis and monitoring.
- Several potential prognostic markers require further investigation.
- Multimarker analysis shows promise for improved prostate cancer management.